Patient preferences for gene therapy in haemophilia : Results from the PAVING threshold technique survey
© 2021 The Authors. Haemophilia published by John Wiley & Sons Ltd..
OBJECTIVES: The aim of the Patient preferences to Assess Value IN Gene therapies (PAVING) study was to investigate trade-offs that adult Belgian people with haemophilia (PWH) A and B are willing to make when choosing between prophylactic factor replacement therapy (PFRT) and gene therapy.
METHODS: The threshold technique was used to quantify the minimum acceptable benefit (MAB) of a switch from PFRT to gene therapy in terms of 'Annual bleeding rate' (ABR), 'Chance to stop prophylaxis' (STOP), and 'Quality of life' (QOL). The design was supported by stakeholder involvement and included an educational tool on gene therapy. Threshold intervals were analysed using interval regression models in Stata 16.
RESULTS: A total of 117 PWH completed the survey. Mean thresholds were identified for all benefits, but substantial preference heterogeneity was observed; especially for the STOP thresholds, where the distribution of preferences was bimodal. Time spent on the educational tool and residence were found to impact MAB thresholds. The most accepted (88% of PWH) gene therapy profile investigated in this study comprised of zero bleeds per year (vs. six for PFRT), 90% chance to stop prophylaxis, no impact on QoL, and 10 years of follow-up on side effects (vs. 30 for PFRT).
CONCLUSIONS: Results from this study proved the value of educating patients on novel treatments. Moreover, preference heterogeneity for novel treatments was confirmed in this study. In gene therapy decision-making, preference heterogeneity and the impact of patient education on acceptance should be considered.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
---|---|
Enthalten in: |
Haemophilia : the official journal of the World Federation of Hemophilia - 27(2021), 6 vom: 09. Nov., Seite 957-966 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
van Overbeeke, Eline [VerfasserIn] |
---|
Links: |
---|
Themen: |
Gene therapy |
---|
Anmerkungen: |
Date Completed 10.11.2021 Date Revised 31.07.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/hae.14401 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM33014684X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM33014684X | ||
003 | DE-627 | ||
005 | 20231225210649.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/hae.14401 |2 doi | |
028 | 5 | 2 | |a pubmed24n1100.xml |
035 | |a (DE-627)NLM33014684X | ||
035 | |a (NLM)34472162 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a van Overbeeke, Eline |e verfasserin |4 aut | |
245 | 1 | 0 | |a Patient preferences for gene therapy in haemophilia |b Results from the PAVING threshold technique survey |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 10.11.2021 | ||
500 | |a Date Revised 31.07.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021 The Authors. Haemophilia published by John Wiley & Sons Ltd. | ||
520 | |a OBJECTIVES: The aim of the Patient preferences to Assess Value IN Gene therapies (PAVING) study was to investigate trade-offs that adult Belgian people with haemophilia (PWH) A and B are willing to make when choosing between prophylactic factor replacement therapy (PFRT) and gene therapy | ||
520 | |a METHODS: The threshold technique was used to quantify the minimum acceptable benefit (MAB) of a switch from PFRT to gene therapy in terms of 'Annual bleeding rate' (ABR), 'Chance to stop prophylaxis' (STOP), and 'Quality of life' (QOL). The design was supported by stakeholder involvement and included an educational tool on gene therapy. Threshold intervals were analysed using interval regression models in Stata 16 | ||
520 | |a RESULTS: A total of 117 PWH completed the survey. Mean thresholds were identified for all benefits, but substantial preference heterogeneity was observed; especially for the STOP thresholds, where the distribution of preferences was bimodal. Time spent on the educational tool and residence were found to impact MAB thresholds. The most accepted (88% of PWH) gene therapy profile investigated in this study comprised of zero bleeds per year (vs. six for PFRT), 90% chance to stop prophylaxis, no impact on QoL, and 10 years of follow-up on side effects (vs. 30 for PFRT) | ||
520 | |a CONCLUSIONS: Results from this study proved the value of educating patients on novel treatments. Moreover, preference heterogeneity for novel treatments was confirmed in this study. In gene therapy decision-making, preference heterogeneity and the impact of patient education on acceptance should be considered | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a gene therapy | |
650 | 4 | |a haemophilia | |
650 | 4 | |a perspectives | |
650 | 4 | |a preference | |
650 | 4 | |a questionnaire | |
650 | 4 | |a survey | |
700 | 1 | |a Hauber, Brett |e verfasserin |4 aut | |
700 | 1 | |a Michelsen, Sissel |e verfasserin |4 aut | |
700 | 1 | |a Peerlinck, Kathelijne |e verfasserin |4 aut | |
700 | 1 | |a Lambert, Catherine |e verfasserin |4 aut | |
700 | 1 | |a Hermans, Cedric |e verfasserin |4 aut | |
700 | 1 | |a Lê, Phu Quoc |e verfasserin |4 aut | |
700 | 1 | |a Goldman, Michel |e verfasserin |4 aut | |
700 | 1 | |a Simoens, Steven |e verfasserin |4 aut | |
700 | 1 | |a Huys, Isabelle |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Haemophilia : the official journal of the World Federation of Hemophilia |d 1995 |g 27(2021), 6 vom: 09. Nov., Seite 957-966 |w (DE-627)NLM093860773 |x 1365-2516 |7 nnns |
773 | 1 | 8 | |g volume:27 |g year:2021 |g number:6 |g day:09 |g month:11 |g pages:957-966 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/hae.14401 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 27 |j 2021 |e 6 |b 09 |c 11 |h 957-966 |